Verastem, Inc.
Headquarters country
United States
Registry sponsor category
Industry
- Other names
- Verastem, Inc.
- Company name
- Verastem, Inc.
- Organisation type
- Industry
- Registered legal name
- VERASTEM, INC.
- US industry code (SIC)
- Pharmaceutical preparations
- Registry sponsor category
- Industry
- Website
- https://www.verastem.com
- Headquarters country
- United States
- Publicly traded (proxy)
- Yes
- Listing at source
- Listed
- SEC filer number (CIK)
- 0001526119
- Legal Entity Identifier (LEI)
- 549300IY0EFBIU8NQC81
- Wikidata ID
- Q30289308
Related records
Trials (50)
- 5G-RUBY: Avutometinib and Defactinib in Malignant Brain Tumours
- A Phase 1 Dose Escalation Study of VS-5584 Administered in Combination With VS-6063, in Subjects With Relapsed Malignant Mesothelioma
- A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors
- A Phase 2 Study of Avutometinib (VS-6766) Plus Defactinib
- A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Colorectal Cancer
- A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Non-Small Cell Lung Cancer
- A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Pancreatic Cancer
- A Phase I, Open-label Study of Absorption, Metabolism, and Excretion of Defactinib (VS-6063) in Healthy Male Subjects
- A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian Cancer
- A Study of Avutometinib (VS-6766) + Defactinib in Recurrent KRAS G12V, Other KRAS and BRAF Non-Small Cell Lung Cancer
- A Study of Avutometinib (VS-6766) and Defactinib in People With Mesonephric Gynecologic Cancer
- A Study of Avutometinib (VS-6766) v. Avutometinib (VS-6766) + Defactinib in Recurrent Low-Grade Serous Ovarian Cancer With and Without a KRAS Mutation
- A Study of Avutometinib + Defactinib in Recurrent Low-Grade Serous Ovarian Cancer in Japanese Patients
- A Study of Avutometinib and Defactinib in People With Thyroid Cancer
- A Study of Avutometinib, Defactinib, and Letrozole in People With Low-Grade Serous Ovarian Cancer
- A Study Of PF-04554878 In Patients With Advanced Non-Hematologic Malignancies
- A Study of VS-6766 and Cetuximab in Patients With Advanced Colorectal Cancer
- Avutometinib and Defactinib in Diffuse Gastric Cancer
- Continued Access to Avutometinib in Combination With Defactinib in Patients With Recurrent Low-Grade Serous Ovarian Cancer (LGSOC)
- Defactinib and Avutometinib, With or Without Encorafenib, for the Treatment of Patients With Brain Metastases From Cutaneous Melanoma